Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Long-Term Investments (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Investments for 11 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments changed 0.0% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 0.0% change, with the full-year FY2024 number at $2.0 million, changed 0.0% from a year prior.
  • Long-Term Investments was $2.0 million for Q3 2025 at Cartesian Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $2.0 million in Q3 2021 to a low of $2.0 million in Q3 2021.
  • A 5-year average of $2.0 million and a median of $2.0 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 45.03% in 2021, then changed 0.0% in 2022.
  • Cartesian Therapeutics' Long-Term Investments stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Long-Term Investments are $2.0 million (Q3 2025), $2.0 million (Q2 2025), and $2.0 million (Q1 2025).